The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
Maria Letizia Cataldo(Baylor College of Medicine), Bianca Maria Veneziani(Federico II University Hospital), Daniela Esposito(University of Naples Federico II), Pietro De Placido(University of Naples Federico II), Roberto Bianco(Federico II University Hospital), Luigi Formisano(Federico II University Hospital), Mario Giuliano(Regione Campania), Grazia Arpino(University of Naples Federico II), Carmine De Angelis(Baylor College of Medicine)
Cited by 18
Related Papers
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273